It is important to note that since the autoantigen(s) in MS remain unknown and are likely heterogenous between and even within individual patients, we chose to activate TEM CD8+ T cells derived from healthy controls by crosslinking TCR rather than introducing a bias by picking specific peptides and types of patients. This evidence concerns the gene CD8A and myeloid sarcoma.